Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin's Lymphoma: a Single Institute Experience

  • Ozdemir, Nuriye (Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University) ;
  • Dogan, Mutlu (Department of Medical Oncology, Ankara Numune Education and Research Hospital) ;
  • Sendur, Mehmet Ali Nahit (Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University) ;
  • Yazici, Ozan (Department of Medical Oncology, Ankara Numune Education and Research Hospital) ;
  • Abali, Huseyin (Department of Medical Oncology, Hacettepe University Cancer Institute) ;
  • Yazilitas, Dogan (Department of Medical Oncology, Ankara Numune Education and Research Hospital) ;
  • Akinci, Muhammed Bulent (Department of Medical Oncology, Faculty of Medicine, Yildirim Beyazit University) ;
  • Aksoy, Sercan (Department of Medical Oncology, Faculty of Medicine, Adana Baskent University) ;
  • Zengi, Nurullah (Department of Medical Oncology, Ankara Numune Education and Research Hospital)
  • Published : 2014.11.06
Download PDF
⟨ Previous Next ⟩

Abstract

Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen in Hodgkin's lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacy and safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. Stage I-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute Common Toxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007 were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their third decade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% for early relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4% for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients had autologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longer in early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02; respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT (p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicity-related deaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poor prognostic factors.

Keywords

References

  1. Abu-Khalaf MM HL (2011). Antimicrotubule agents. In: DeVita VT, Lawrence TS, Rosenberg SA, Editors. Cancer Principles and Practice of Oncology. Philedelphia: Lippincott Williams and Wilkins. 413-21.
  2. Advani RH, Hoppe RT, Baer D, et al (2013). Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol, 24, 1044-8. https://doi.org/10.1093/annonc/mds542
  3. Bonadonna G, Zucali R, Monfardini S, et al (1975). Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer, 36, 252-9. https://doi.org/10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
  4. Canellos GP, Anderson JR, Propert KJ, et al (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 327, 1478-84. https://doi.org/10.1056/NEJM199211193272102
  5. Chakrabarti S, Sarkar S, Goswami BK, et al (2010). Hodgkin's and non-Hodgkin's lymphomas in an indian rural medical institution: comparative clinicopathologic analysis. Asian Pac J Cancer Prev, 11, 1605-8.
  6. Cullen MH, Stuart NS, Woodroffe C, et al (1994). ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. J Clin Oncol, 12, 779-87.
  7. Diehl V, Franklin J, Hasenclever D, et al (1998). BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 16, 3810-21.
  8. Engert A, Diehl V, Franklin J, et al (2009). Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol, 27, 4548-54. https://doi.org/10.1200/JCO.2008.19.8820
  9. Fatima S, Ahmed R, Ahmed A (2011). Hodgkin lymphoma in Pakistan: an analysis of subtypes and their correlation with Epstein Barr virus. Asian Pac J Cancer Prev, 12, 1385-8.
  10. Hancock BW, Gregory WM, Cullen MH, et al (2001). ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer, 84, 1293-300. https://doi.org/10.1054/bjoc.2001.1778
  11. Meyer RM, Gospodarowicz MK, Connors JM, et al (2005). Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol, 23, 4634-42. https://doi.org/10.1200/JCO.2005.09.085
  12. Meyer RM, Gospodarowicz MK, Connors JM, et al (2012). ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med, 366, 399-408. https://doi.org/10.1056/NEJMoa1111961
  13. Viviani S, Zinzani PL, Rambaldi A, et al (2011). ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med, 365, 203-12. https://doi.org/10.1056/NEJMoa1100340